A population-based study of primary chemoradiotherapy in clinical stage III non-small cell lung cancer: Intensity-modulated radiotherapy versus 3D conformal radiotherapy

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 5175-5180

  Hsia, T E Chun ^a   Tu, Chih Yen ^a   Chen, Hung Jen ^a   Chen, Shuo Chueh ^a   Liang, J I A N ^a   Chen, Chih Y I ^a   Wang, Yao Ching ^a   Chien, Chun R U ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

3DCRT; IMRT; Lung cancer; Population based study.

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; 3DCRT; HEALTH SURVEY; KAPLAN MEIER METHOD; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POPULATION-BASED STUDY; TREATMENT OUTCOME; VERY ELDERLY;

3DCRT; IMRT; LUNG CANCER; POPULATION-BASED STUDY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 84908661616     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. De Ruysscher D, Belderbos J, Reymen B, van Elmpt W, van Baardwijk A, Wanders R, Hoebers F, Vooijs M, Ollers M and Lambin P: State of the art radiation therapy for lung cancer 2012: a glimpse of the future. Clinical lung cancer 14: 89-95, 2013.
2. McCloskey P, Balduyck B, Van Schil PE, Faivre-Finn C and O'Brien M: Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer 49: 1555-1564, 2013.
3. NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer 2014v4. Available at http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed June 19, 2014
4. Chapet O, Khodri M, Jalade P, N'Guyen D, Flandin I, D'Hombres A, Romestaing P and Mornex F: Potential benefits of using non coplanar field and intensity-modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes. Radiother Oncol 80: 333-340, 2006.
5. Guckenberger M, Kavanagh A and Partridge M: Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer. Strahlenther Onkol 188: 894-900, 2012.
6. Soyfer V, Meir Y, Corn BW, Schifter D, Gez E, Tempelhoff H and Shtraus N: AP-PA field orientation followed by IMRT reduces lung exposure in comparison to conventional 3D conformal and sole IMRT in centrally located lung tumors. Radiat Oncol 7: 23, 2012.
7. Simeonova A, Abo-Madyan Y, El-Haddad M, Welzel G, Polednik M, Boggula R, Wenz F and Lohr F: Comparison of anisotropic aperture based intensity modulated radiotherapy with 3D-conformal radiotherapy for the treatment of large lung tumors. Radiother Oncol 102: 268-273, 2012
8. Sura S, Gupta V, Yorke E, Jackson A, Amols H and Rosenzweig KE: Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87: 17-23, 2008.
9. Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA and Smith BD: Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities. Lung Cancer 82: 252-259, 2013.
10. Liao ZX, Komaki RR, Thames HD Jr., Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blmenschein G, Hong WK and Cox JD: Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76: 775-781, 2010.
11. Wang YC, Chen SW, Chien CR, Hsieh TC, Yu CY, Kuo YC, Yang SN, Kao CH and Liang JA: Radiotherapy for esophageal cancer using simultaneous integrated boost techniques: dosimetric comparison of helical tomotherapy, volumetric-modulated arc therapy (RapidArc) and dynamic intensity-modulated radiotherapy. Technol Cancer Res Treat 12: 485-491, 2013.
12. Allen AM, Czerminska M, Janne PA, Sugarbaker DJ, Bueno R, Harris JR, Court L and Baldini EH: Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65: 640-645, 2006.
13. Bezjak A, Rumble RB, Rodrigues G, Hope A, Warde P, Members of the IIEP: Intensity-modulated radiotherapy in the treatment of lung cancer. Clin Oncol (R Coll Radiol) 24: 508-520, 2012.
14. Hsia TC, Tu CY, Chen HJ and Chien CR: Effectiveness of intensity-modulated radiotherapy for lung cancer. Clin Oncol (R Coll Radiol) 25: 447-48, 2013.
15. The Collaboration Center of Health Information Application (CCHIA). available at http://nhip.mohw.gov.tw/nhip/eng/index.html Accessed June 19, 2014.
16. Taiwan Cancer Registry. Available at http://tcr.cph.ntu.edu.tw/main.php?Page=N1. Accessed June 19, 2014.
17. National Health Insurance Website. Available at http://www.nhi.gov.tw/english/index.aspx. Accessed June 19, 2014.
18. National Health Insurance Introduction. Available at http://www.nhi.gov.tw/Resource/webdata/21717-1-20120808UniversalHealthCoverage.pdf. Accessed June 19, 2014.
19. Greene FL, American Joint Committee on Cancer Society, AJCC cancer staging manual 6th ed. In: lung, New York: Springer; pp. 170-171, 2002.
20. Code of Federal Regulations. Available at http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html. Accessed June 19, 2014.
21. Chien CR, Lin HW, Yang CH, Yang SN, Wang YC, Kuo YC, Chen SW and Liang JA: High case volume of radiation oncologists is associated with better survival of nasopharyngeal carcinoma patients treated with radiotherapy: a multifactorial cohort analysis. Clin Otolaryngol 36: 558-565, 2011.
22. Chien CR, Yang ST, Chen CY, Fang HY, Tu CY, Tseng GC, Yu YH, Chen HJ, Ho CT, Hsieh CY, Chen HN, Chen PR, Liu JC, Wang YC, Wu HH and Hsia TC: Impact of the new lung cancer staging system for a predominantly advanced-disease patient population. J Thorac Oncol 5: 340-343, 2010.
23. Chien CR, Pan IW, Tsai YW, Tsai T, Liang JA, Buchholz TA and Shih YC: Radiation therapy after breast-conserving surgery: Does hospital surgical volume matter? A population-based study in Taiwan. Int J Radiat Oncol Biol Phys 82: 43-50, 2012.
24. Chen PC, Muo CH, Lee YT, Yu YH and Sung FC: Lung cancer and incidence of stroke: a population-based cohort study. Stroke 42: 3034-3039, 2011.
25. Chien CR, Chen SW, Hsieh CY, Liang JA, Yang SN, Huang CY and Lin FJ: Intra-thoracic failure pattern and survival status following 3D conformal radiotherapy for non-small cell lung cancer: a preliminary report. Jpn J Clin Oncol 31: 55-60, 2001.
26. Fang HY, Chen CY, Wang YC, Wang PH, Shieh SH and Chien CR: Consistently lower narcotics consumption after video-assisted thoracoscopic surgery for early stage non-small cell lung cancer when compared to open surgery: a one-year follow-up study. Eur J Cardiothorac Surg 43: 783-786, 2013.
27. Tsai HH, Lin HW, Chien CR and Li TC: Concurrent use of antiplatelets, anticoagulants, or digoxin with Chinese medications: a population-based cohort study. Eur J Clin Pharmacol 69: 629-639, 2013..
28. Chien CR, Su SY, Cohen L, Lin HW, Lee RT and Shih YC: Use of Chinese medicine among survivors of nasopharyngeal carcinoma in Taiwan: a population-based study. Integr Cancer Ther 11: 221-231, 2012.
29. Lin CC, Hsia TC and Chien CR: 3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world. Lung Cancer 76: 499-500, 2012.
30. Chien CR and Shih YC: Use of personalized decision analysis in decision making for Palliative vs. surgical management of the oldest-old patients with localized skin cancer in a culturally sensitive environment: a case study of a 96-year-old male Taiwanese patient. J Pain Symptom Manage 45: 792-797, 2013.
31. Ke TW, Liao YM, Chiang HC, Chang SC Chang, Wang PH, Chen YY, Chen WT and Chien CR: Effectiveness of neoadjuvant concurrent chemoradiotherapy vs. upfront proctectomy in clinical stage II-III Rectal cancer: a population-based study. Asia Pac J Clin Oncol, Epub ahead of print, 2014
32. Austin PC, Chiu M, Ko DT, Goeree R and Tu JV: Propensity score matching for estimating treatment effect. In: Analysis of Observational Health Care Data Using SAS. Faries DE, Leon AC, Haro JM, Obenchain RL (eds.). Cary: SAS Institute, pp. 51-84, 2010.
33. Austin PC: A tutorial on the use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33: 1242-1258, 2014.
34. Chen AB: Comparative effectiveness research in radiation oncology: assessing technology. Semin Radiat Oncol 24: 25-34, 2014.
35. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD and Komaki R: Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68: 94-102, 2007.
36. Vogelius IS, Westerly DC, Cannon GM, Mackie TR, Mehta MP, Sugie C and Bentzen SM: Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping. Int J Radiat Oncol Biol Phys 80: 893-899, 2011.
37. Cox JD: Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys 82: 1042-44, 2012.
38. Lin Q, Liu Y, Wang N, Huang Y, Ge X, Ren X, Chen X, Hu J, Guo Z, Zhao Y and Asaumi J: A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small cell lung cancer. J Radiat Res 54: 126-134, 2013.
39. Huang WC, Chen YJ and Hung MC: Implication of nuclear EGFR in the development of resistance to anticancer therapies. BioMedicine 1: 2-10, 2011.
40. Harris JP, Murphy JD, Hanlon AL, Le QT, Loo BW Jr. and Diehn M: A: Population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88: 872-84, 2014.
41. Freilich J, Hoffe SE, Almhanna K, Dinwoodie W, Yue B, Fulp W, Meredith KL and Shridhar R: Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer. Dis Esophagus. Epub ahead of print, 2014.
42. Ma BB, Hui EP and Mok TS: Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 11: 75-84, 2010.